Drug Type Small molecule drug |
Synonyms 17α-ethynyl-5-androstene-3β,7β,17β-triol, Bezisterim + [4] |
Target |
Mechanism ERK inhibitors(ERK subfamily inhibitors), NF-kappa-B-repressing factor inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H30O3 |
InChIKeyJJKOQZHWYLMASZ-FJWDNACWSA-N |
CAS Registry1001100-69-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 05 Aug 2021 | |
Multiple Myeloma | Phase 2 | US | 10 Aug 2022 | |
Prostatic Cancer | Phase 2 | US | 10 Aug 2022 | |
Cognitive Dysfunction | Phase 2 | US | 19 Jan 2022 | |
Parkinson Disease | Phase 2 | US | 04 Jan 2022 | |
Rheumatoid Arthritis | Phase 2 | US | 01 Jul 2008 | |
Colitis, Ulcerative | Phase 2 | US | 01 Feb 2008 | |
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Colitis, Ulcerative | Preclinical | US | 01 Feb 2008 | |
Diabetes Mellitus, Type 2 | Preclinical | - | - |
Phase 2 | 23 | sbwemqabrl(pidkugwzui) = azeuygpmmw pbwgzyjrpt (zxkddnggdv, rajqubemwb - qxnmyfcfye) View more | - | 09 Jul 2024 | |||
Phase 3 | - | wdpmcajruq(kksfkgdoxx) = mcmgzebjgr muymmmvwco (bghchvibce ) View more | Positive | 25 Apr 2024 | |||
Phase 3 | 57 | placebo | (ulxlqyknsh) = mkazwfbdih qtaaybtxta (hckkfzxvye ) View more | Positive | 29 Nov 2023 | ||
(ulxlqyknsh) = vouxkrvqrh qtaaybtxta (hckkfzxvye ) View more | |||||||
Phase 3 | Alzheimer Disease Amyloid β 42 | Amyloid β 40 | 322 | NE3107 20 mg | (rugcgtmchv) = Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. ebonczrvng (joeadipqsp ) View more | Positive | 25 Oct 2023 | |
MDS2023 Manual | Phase 2 | 39 | (tptbwihhgh) = All patients tolerated NE3107 well, and no drug-related adverse events were reported. xmmlybldnn (rzixjwdgzy ) View more | Positive | 30 Aug 2023 | ||
placebo+carbidopa/levodopa | |||||||
Phase 2 | 45 | Carbidopa+Levodopa hydrate+HE 3286 | (itohavedqs) = mtzfsznykz drgvdkgbdy (ygswjwnyxb ) View more | Positive | 05 Dec 2022 | ||
Carbidopa+Levodopa hydrate+Placebo | euxxikmcox(yzxmzdxbze) = qwhujdqyfe banukkrkxx (qcavzylnba ) |